Compare Hubbell (HUBB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hubbell vs Tango Therapeutics Inc. — how do they compare? Hubbell trades at $471.77 (market cap $25.25B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Hubbell is far larger — about 6.7× Tango Therapeutics Inc.'s market cap, and Hubbell pays a 1.19% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hubbell for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| HUBB | TNGX | |
|---|---|---|
Market Cap | $25.25B | $3.75B |
Volume | 443,319 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $557.85 | $32.90 |
52-Week Low | $407.36 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $30.41B | $2.77B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hubbell Incorporated (HUBB) trades at $477.93, up 0.82% with a neutral technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025: $4.73 vs. $4.71 expected, Q1 2026: $3.93 vs. $3.87, Q2 2026: $5.52 vs. $5.39) and robust profitability (net margin 14.49%, ROE 24.34%). Recent news highlights grid modernization opportunities and institutional buying interest from Bank of America and BNY Mellon.
Hubbell presents a favorable outlook with analyst consensus price target of $560.50 (17% upside) and strong institutional support. Key risks include integration challenges from recent acquisitions and dependence on utility spending cycles. The Q3 2026 earnings report on October 27 will be crucial for validating growth trajectory amid electrification demand.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hubbell
Hubbell manufactures electrical and utility products used in transmission, distribution, and electrical infrastructure. Its portfolio includes components and systems for utilities, data centers, industrial facilities, and buildings.
Read more on HUBB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
